James Noble becomes full-time CEO of Adaptimmune
This article was originally published in Scrip
Adaptimmune, a biotechnology company focused on the use of engineered T cells to treat cancer, has named James Noble full-time CEO – effective 31 March 2014. Mr Noble has been CEO of Adaptimmune since its formation in 2008, but until now has been combining this position with his role as CEO of sister company, Immunocore. He will remain on the Board of Immunocore as a non-executive director. Meanwhile, Dr Jonathan Knowles, currently executive chair of both Adaptimmune and Immunocore, will serve as acting CEO of Immunocore until the company's board appoints a permanent replacement. The move comes as both companies are "at the stage where they each require a full-time CEO to lead further development," said Adaptimmune.
You may also be interested in...
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.